Pharmacoeconomic aspects of the treatment of onychomycosis;Aspects pharmaco-économiques des onychomycoses

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 12 II, 2003, Pages 1272-1274

  Lambert, J ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; ONYCHOMYCOSIS; TREATMENT OUTCOME;

HUMANS; ONYCHOMYCOSIS;

EID: 0347415695     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Berdeaux G. Economie de la santé, pharmaco-économie et prescriptions en dermatologie. Ann Dermatol Venereol 2000;127:324-8.
2. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130(Suppl 43):32-4.
3. Arikian SR, Einarson TR, Kobelt Ngnyen G, Schubert F and the onychomycosis study group. A multinational pharmaco-economic analysis of oral therapies for onychomycosis. Br J Dermatol 1994;130(Suppl 43):35-44.
4. Marchetti A, Piech CT, McGhan WF, Neugut AT, Smith B. Pharmacoeconomic analysis of oral therapies for onychomycosis. A US model. Clin Ther 1996;18:757-77.
5. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998;13:243-56.
6. Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol 1999;38(suppl2):53-64.
7. van Doorslaer E, Tormans G, Gupta AK, van Rossem K, van Rossem K, Eggleston A, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996;193:239-44.
8. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000;43:S81-95.
9. Baran R, Feuilhade M, Datry A, Goetmann S, Pietrini S, Viguie R, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000;142:1177-83.
10. Lecha M, Alsina M, Torres-Rodriguez JM, de Erenchun FR, Mirada A Rossi AB. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002;63:366-79.
11. Lambert J. Pharmacoeconomic issues in onychomycosis. Br J Dermatol 2003;149:19-22.